A new partnership to improve TB treatments around the world


endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels.

Covering 17 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partner UNITAID.

Watch the two-minute animation


You can contact us, or follow us on Twitter.

New TB drugs are safe, effective alternatives

Patient holding his medication, he takes up to 26 pills a day to treat XDR-TB. Here he holds his morning selection, which includes delamanid, one of the newest DR-TB drugs, which he is taking for the first time today.


13 July 2018

New interim findings from endTB indicate bedaquiline and delamanid could benefit many more patients.

Read more

Clinical Trial Investigators Meeting

Clinical Trial Investigators Meeting


30 October 2018

endTB clinical trial investigators and study coordinators successfully complete first annual Investigators Meeting in Paris. 

Read more